Targeting butyrylcholinesterase for preclinical single photon emission computed tomography (SPECT) imaging of Alzheimer's disease

  title={Targeting butyrylcholinesterase for preclinical single photon emission computed tomography (SPECT) imaging of Alzheimer's disease},
  author={Drew Debay and George Andrew Reid and Ian R Pottie and Earl F. Martin and Chris V Bowen and Sultan Darvesh},
  journal={Alzheimer's \& Dementia : Translational Research \& Clinical Interventions},
  pages={166 - 176}
  • D. Debay, G. Reid, +3 authors S. Darvesh
  • Published 2017
  • Chemistry, Medicine
  • Alzheimer's & Dementia : Translational Research & Clinical Interventions
Diagnosis of Alzheimer's disease (AD) in vivo, by molecular imaging of amyloid or tau, is constrained because similar changes can be found in brains of cognitively normal individuals. Butyrylcholinesterase (BChE), which becomes associated with these structures in AD, could elevate the accuracy of AD diagnosis by focusing on BChE pathology in the cerebral cortex, a region of scant BChE activity in healthy brain. 
Longitudinal evaluation of a novel BChE PET tracer as an early in vivo biomarker in the brain of a mouse model for Alzheimer disease
11C-labeling, in vivo stability, biodistribution, and longitudinal study on BChE abundance in the brains of control and 5xFAD (AD model) animals are reported, suggesting that B ChE is a promising early biomarker for incipient AD. Expand
Quantification of Butyrylcholinesterase Activity as a Sensitive and Specific Biomarker of Alzheimer’s Disease
The predictive value of BChE as a biomarker for AD that could facilitate timely disease diagnosis and management is highlighted and is compared to Aβ, thioflavin-S, and BE quantification of 26 postmortem brain tissues. Expand
Imaging Butyrylcholinesterase in Multiple Sclerosis
BChE Imaging agents have the potential to detect MS lesions and subtle pathology in normal-appearing white matter in postmortem MS brain tissue and the possibility of BChE imaging agents serving to supplement current diagnostic and treatment monitoring strategies should be evaluated. Expand
Cholinesterases in normal and Alzheimer's disease primary olfactory gyrus
The anatomical and cholinergic organization of the POG in normal human brain and neuropathology in AD is examined, indicating early involvement of pathology in olfactory structures. Expand
Nanomaterial-based Optical and Electrochemical Biosensors for Amyloid beta and Tau: Potential for early diagnosis of Alzheimer’s Disease
The study has identified the potential application of advanced biosensors as standardized clinical diagnostic tools for AD, evolving the way for new and efficient AD control with minimum economic and social burden. Expand
Conceptualization of computational modeling approaches and interpretation of the role of neuroimaging indices in pathomechanisms for pre-clinical detection of Alzheimer Disease
The benefit of this work, to use high quality and context specific data, becomes apparent in speculating previously unattended biomarker candidates around a well-known mechanism, further leveraged for experimental investigations. Expand
Butyrylcholinesterase: A Multifaceted Pharmacological Target and Tool.
The biochemical properties of butyrylcholinesterase and its roles, as cholinergic neurotransmitor, in various diseases, particularly neurodegenerative disorders are reviewed. Expand
Preventive effect of N-stearoylethanolamine on memory disorders, blood and brain biochemical parameters in rats with experimental scopolamine-induced cognitive impairment
NSe action was associated with the prevention of increase in acetylcholinesterase activity, changes in phospholipid, free and esterified cholesterol level in hippocampus and frontal cortex, and disruption in pro-/antioxidant balance in blood and studied brain sections. Expand
Synthesis and Initial Characterization of a Reversible, Selective 18F-Labeled Radiotracer for Human Butyrylcholinesterase
This study presents the synthesis, radiochemistry, in vitro and preliminary ex and in vivo investigations of a selective, reversible BChE inhibitor as PET-tracer for evaluation as an AD diagnostic and reveals the reversibly acting, selective radiotracer is synthetically easily accessible and retains promising activity and binding potential on hBChE. Expand


Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study
Evaluation of brain β‐amyloid by positron emission tomography (PET) imaging can assist in the diagnosis of Alzheimer disease (AD) and other dementias.
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
The results suggest that PET imaging with the novel tracer, PIB, can provide quantitative information on amyloid deposits in living subjects. Expand
Application of pet imaging to diagnosis of Alzheimer's disease and mild cognitive impairment.
Advice is given for use of PET in primary settings and referral centers, approach to its interpretation, and outline a clinical prediction model based on findings. Expand
Visual Versus Fully Automated Analyses of 18F-FDG and Amyloid PET for Prediction of Dementia Due to Alzheimer Disease in Mild Cognitive Impairment
Both 18F-FDG and 11C-PiB imaging appear to be of limited use for predicting the progression from MCI to dementia due to AD in short-term follow-up, irrespective of the strategy of analysis, while amyloid PET is extremely useful to rule out underlying AD. Expand
Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between β-Amyloid and Tauopathy.
Use of [18F]-AV-1451 has a potential for staging of the preclinical and clinical phases of AD and the associations among β-amyloid, tau, and volume loss are assessed. Expand
Butyrylcholinesterase and progression of cognitive deficits in dementia with Lewy bodies
A highly significant association between temporal cortex butyrylcholinesterase activity and the rate of cognitive decline in a prospectively studied, autopsy-confirmed dementia with Lewy bodies series is reported. Expand
Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density.
This study showed that flutemetamol injection labeled with radioactive fluorine 18 was safe and had high sensitivity and specificity in an end-of-life population and may increase diagnostic accuracy in cognitively impaired patients. Expand
Synthesis and evaluation of 18F-labeled 2-phenylbenzothiazoles as positron emission tomography imaging agents for amyloid plaques in Alzheimer's disease.
The preliminary results strongly suggest that this new fluorinated compound is a promising candidate as an Abeta plaque imaging agent for the study of patients with Alzheimer's disease. Expand
Butyrylcholinesterase-knockout reduces brain deposition of fibrillar β-amyloid in an Alzheimer mouse model
The Knock-out of BChE in this model showed diminished fibrillar Aβ plaque deposition, more so in males than females, suggesting that lack of B ChE reduces deposition of fibrilar A β in AD and this effect may be influenced by sex. Expand
Early Detection of Cerebral Glucose Uptake Changes in the 5XFAD Mouse
It is concluded that brain 18FDG uptake can be a sensitive biomarker for early detection of abnormal metabolism in the 5XFAD mouse when alternative relative uptake values are utilized. Expand